CPRX.NASDAQCatalyst Pharmaceuticals, INC

Form 4: Catalyst Pharmaceuticals CEO Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)

📋All filings for Catalyst Pharmaceuticals, INC
🔒Login to Follow

Richard J Daly, President and CEO and a Director of Catalyst Pharmaceuticals, Inc., reported multiple transactions in common stock on July 15, 2026.

Summary

  • Disposition to the issuer: disposed of 271,266 Common Stock, par value $0.001 per share at $31.50 ($8,544,879) on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 33,500 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 30,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 20,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 15,000 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 1,365,319 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 491,160 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 381,948 Options to purchase common stock on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 126,316 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 40,013 Restricted Stock Units on July 15, 2026 (Direct).
  • Disposition to the issuer: disposed of 115,283 Restricted Stock Units on July 15, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Richard J Daly — Director, Officer (President and CEO)

DateTransactionSecuritySharesPriceValueHeld After
2026-07-15Disposition to the issuerCommon Stock, par value $0.001 per share271,266$32$8.5M0
2026-07-15Disposition to the issuerOptions to purchase common stock33,500——0
2026-07-15Disposition to the issuerOptions to purchase common stock30,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock20,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock15,000——0
2026-07-15Disposition to the issuerOptions to purchase common stock1,365,319——0
2026-07-15Disposition to the issuerOptions to purchase common stock491,160——0
2026-07-15Disposition to the issuerOptions to purchase common stock381,948——0
2026-07-15Disposition to the issuerRestricted Stock Units126,316——0
2026-07-15Disposition to the issuerRestricted Stock Units40,013——0
2026-07-15Disposition to the issuerRestricted Stock Units115,283——0

Key Dates

DateDescription
2026-07-15Disposition to the issuer (271,266 shares)
2026-07-15Disposition to the issuer (33,500 shares)
2026-07-15Disposition to the issuer (30,000 shares)
2026-07-15Disposition to the issuer (20,000 shares)
2026-07-15Disposition to the issuer (15,000 shares)
2026-07-15Disposition to the issuer (1,365,319 shares)
2026-07-15Disposition to the issuer (491,160 shares)
2026-07-15Disposition to the issuer (381,948 shares)
2026-07-15Disposition to the issuer (126,316 shares)
2026-07-15Disposition to the issuer (40,013 shares)
2026-07-15Disposition to the issuer (115,283 shares)

Keywords

insider transaction, Form 4, CPRX, CATALYST PHARMACEUTICALS, INC., neutral, Richard J Daly

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.